OBJECTIVES: A high body mass index (BMI) in middle-age or a decrease in BMI at late-age has been considered a predictor for the development of Alzheimer's disease (AD). However, little is known about the BMI change close to or after AD onset. METHODS: BMI of participants from three cohorts, the Washington Heights and Inwood Columbia Aging Project (WHICAP; population-based) and the Predictors Study (clinic-based), and National Alzheimer's Coordinating Center (NACC; clinic-based) were analyzed longitudinally. We used generalized estimating equations to test whether there were significant changes of BMI over time, adjusting for age, sex, education, race, and research center. Stratification analyses were run to determine whether BMI changes depended on baseline BMI status. RESULTS: BMI declined over time up to AD clinical onset, with an annual decrease of 0.21 (p=0.02) in WHICAP and 0.18 (p=0.04) kg/m2 in NACC. After clinical onset of AD, there was no significant decrease of BMI. BMI even increased (b=0.11, p=0.004) among prevalent AD participants in NACC. During the prodromal period, BMI decreased over time in overweight (BMI≥25 and <30) WHICAP participants or obese (BMI≥30) NACC participants. After AD onset, BMI tended to increase in underweight/normal weight (BMI<25) patients and decrease in obese patients in all three cohorts, although the results were significant in NACC study only. CONCLUSIONS: Our study suggests that while BMI declines before the clinical AD onset, it levels off after clinical AD onset, and might even increase in prevalent AD. The pattern of BMI change may also depend on the initial BMI.
OBJECTIVES: A high body mass index (BMI) in middle-age or a decrease in BMI at late-age has been considered a predictor for the development of Alzheimer's disease (AD). However, little is known about the BMI change close to or after AD onset. METHODS: BMI of participants from three cohorts, the Washington Heights and Inwood Columbia Aging Project (WHICAP; population-based) and the Predictors Study (clinic-based), and National Alzheimer's Coordinating Center (NACC; clinic-based) were analyzed longitudinally. We used generalized estimating equations to test whether there were significant changes of BMI over time, adjusting for age, sex, education, race, and research center. Stratification analyses were run to determine whether BMI changes depended on baseline BMI status. RESULTS: BMI declined over time up to AD clinical onset, with an annual decrease of 0.21 (p=0.02) in WHICAP and 0.18 (p=0.04) kg/m2 in NACC. After clinical onset of AD, there was no significant decrease of BMI. BMI even increased (b=0.11, p=0.004) among prevalent ADparticipants in NACC. During the prodromal period, BMI decreased over time in overweight (BMI≥25 and <30) WHICAP participants or obese (BMI≥30) NACCparticipants. After AD onset, BMI tended to increase in underweight/normal weight (BMI<25) patients and decrease in obesepatients in all three cohorts, although the results were significant in NACC study only. CONCLUSIONS: Our study suggests that while BMI declines before the clinical AD onset, it levels off after clinical AD onset, and might even increase in prevalent AD. The pattern of BMI change may also depend on the initial BMI.
Authors: M F Jefferson; S Burlinson; A Burns; D Mann; S Pickering-Brown; F Owen; C Sriwardhana; N Pendleton; M A Horan Journal: Int J Geriatr Psychiatry Date: 2001-01 Impact factor: 3.485
Authors: M Vanhanen; M Kivipelto; K Koivisto; J Kuusisto; L Mykkänen; E L Helkala; T Hänninen; K Kervinen; Y A Kesäniemi; M P Laakso; H Soininen; M Laakso Journal: Neurology Date: 2001-03-13 Impact factor: 9.910
Authors: Brittany N Dugger; Michael Malek-Ahmadi; Sarah E Monsell; Walter A Kukull; Bryan K Woodruff; Eric M Reiman; Thomas G Beach; Jeffrey Wilson Journal: Alzheimer Dis Assoc Disord Date: 2016 Jul-Sep Impact factor: 2.703
Authors: Tomáš Zeman; Vladimir J Balcar; Kamila Cahová; Jana Janoutová; Vladimír Janout; Jan Lochman; Omar Šerý Journal: Mol Neurobiol Date: 2020-10-18 Impact factor: 5.590
Authors: Thomas G Beach; Charles H Adler; Lucia I Sue; Geidy Serrano; Holly A Shill; Douglas G Walker; LihFen Lue; Alex E Roher; Brittany N Dugger; Chera Maarouf; Alex C Birdsill; Anthony Intorcia; Megan Saxon-Labelle; Joel Pullen; Alexander Scroggins; Jessica Filon; Sarah Scott; Brittany Hoffman; Angelica Garcia; John N Caviness; Joseph G Hentz; Erika Driver-Dunckley; Sandra A Jacobson; Kathryn J Davis; Christine M Belden; Kathy E Long; Michael Malek-Ahmadi; Jessica J Powell; Lisa D Gale; Lisa R Nicholson; Richard J Caselli; Bryan K Woodruff; Steven Z Rapscak; Geoffrey L Ahern; Jiong Shi; Anna D Burke; Eric M Reiman; Marwan N Sabbagh Journal: Neuropathology Date: 2015-01-26 Impact factor: 1.906
Authors: Michael L Alosco; Jonathan Duskin; Lilah M Besser; Brett Martin; Christine E Chaisson; John Gunstad; Neil W Kowall; Ann C McKee; Robert A Stern; Yorghos Tripodis Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Rachel M Shaffer; Ge Li; Sara D Adar; C Dirk Keene; Caitlin S Latimer; Paul K Crane; Eric B Larson; Joel D Kaufman; Marco Carone; Lianne Sheppard Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Antonio J López-Gambero; Cristina Rosell-Valle; Dina Medina-Vera; Juan Antonio Navarro; Antonio Vargas; Patricia Rivera; Carlos Sanjuan; Fernando Rodríguez de Fonseca; Juan Suárez Journal: Int J Mol Sci Date: 2021-05-20 Impact factor: 5.923